IgA肾病是我国及亚洲地区发病率最高的原发性肾小球疾病，也是导致终末期肾病的主要原因，西医治疗目前仍无特异性的药物。已故国医大师任继学教授认为本病病机核心为肾虚脾亏，咽喉是发病之关键。首次运用补肾健脾、解毒利咽法治疗IgA肾病，临床应用40年，疗效显著。本课题组前期依托吉林省科技厅、吉林省中医药管理局等项目，证实补肾健脾、解毒利咽法能够调节Th1/Th2失衡及干预MMP-9、TIMP-1表达，从而减轻IgA肾病肾损伤。本课题组拟在前期研究基础上，以黏膜-骨髓轴为主线，采用动物实验和体外细胞实验相结合的研究方式，进一步探讨补肾健脾、解毒利咽法干预IgA分泌细胞的黏膜-骨髓迁移机制及减轻肾损伤的具体环节及作用靶点，从而阐明该疗法在IgA肾病发病及肾小球损伤中的分子调控机制，为该疗法治疗IgA肾病奠定可靠的实验基础，并阐明其科学内涵。

IgA nephropathy is the highest morbidity Primary glomerular disease in china and Asia which is the leading cause of end-stage renal disease. Modern medicine do not have specific drug for it. The late Chinese Medicine Master Renjixue considered Pishenkuixv is the core pathogenesis, throat is the key of onset. Professor Renjixue initiated Bushenjianpi and Jieduliyan method for IgAN which has been practiced for 40 years with a significant effect. The study group relied on program of Chinese Medicine Administration Bureau and Science and Technology Department of Jilin Province proved Bushenjianpi and Jieduliyan method could kidney damage of IgAN by adjusting Th1/Th2 and intervening the expression of MMP-9 and TIMP-1. Our study group wants to use the combine of animal experiments and vitro cell experiments which is based on mucosa - bone marrow axis to further discuss the mucosa - bone marrow migration mechanism of IgA secreting cells and intervention sectors and targets of our method for kidney damage, to clarify molecular regulatory mechanism of Bushenjianpi and Jieduliyan for glomerular injury and IgAN pathogenesis. Establish experimental basis for IgAN and expound the scientific connotation.